Home
Suven Pharmaceuticals Ltd EPS

Suven Pharmaceuticals Ltd
NSE: SUVENPHAR
EPS
Key Highlights
- The Earning per Share of Suven Pharmaceuticals Ltd is ₹ 10.97 as of 07 Apr 25 .
- The earning per share of Suven Pharmaceuticals Ltd changed from ₹ 4.74 to ₹ 3.26 over 7 quarters. This represents a CAGR of -19.26% .
Historical Earning per Share of Suven Pharmaceuticals Ltd
EPS, or Earnings Per Share, is a financial metric that represents the portion of a company's profit allocated to each outstanding share of common stock. It indicates a company's profitability and is calculated by dividing net income by the number of outstanding shares.
Historical Earning per Share of Suven Pharmaceuticals Ltd
Company Fundamentals for Suven Pharmaceuticals Ltd
Market Cap
26,804 Cr
EPS
11.0
P/E Ratio (TTM)
96.0
P/B Ratio (TTM)
13.6
Day’s High
1074.0
Day’s Low
953.05
DTE
0.0
ROE
12.3
52 Week High
1359.0
52 Week Low
597.0
ROCE
15.3
Market Price of Suven Pharmaceuticals Ltd
1M
1Y
3Y
5Y
Last Ten Days Market Price
Date | |
---|---|
07 Apr 2025 | 1052.95 |
04 Apr 2025 | 1086.3 |
03 Apr 2025 | 1125.25 |
02 Apr 2025 | 1093.65 |
01 Apr 2025 | 1074.5 |
28 Mar 2025 | 1159.8 |
27 Mar 2025 | 1109.3 |
26 Mar 2025 | 1113.4 |
25 Mar 2025 | 1151.75 |
24 Mar 2025 | 1173.95 |
SWOT Analysis Of Suven Pharmaceuticals Ltd
BlinkX Score for Suven Pharmaceuticals Ltd
Asset Value vs Market Value of Suven Pharmaceuticals Ltd
Market Value
₹ 26,804
Asset Value
Value addition
53.3 X
₹ 494
* All values are in ₹ crores
Competitive Comparison of EPS
Company | Market Cap | EPS |
---|
Suven Pharmaceuticals Ltd | 26804 | 10.97 |
Sun Pharmaceutical Industries Ltd | 400293 | 49.16 |
Divis Laboratories Ltd | 139692 | 77.86 |
Cipla Ltd | 111807 | 61.78 |
Torrent Pharmaceuticals Ltd | 109399 | 55.02 |
Mankind Pharma Ltd | 98130 | 49.48 |
Company | |
---|---|
Suven Pharmaceuticals Ltd | 26804 |
Sun Pharmaceutical Industries Ltd | 400293 |
Divis Laboratories Ltd | 139692 |
Cipla Ltd | 111807 |
Torrent Pharmaceuticals Ltd | 109399 |
Mankind Pharma Ltd | 98130 |
Historical Market Cap of Suven Pharmaceuticals Ltd
Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore
Historical Market Cap of Suven Pharmaceuticals Ltd
Historical Revenue of Suven Pharmaceuticals Ltd
Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services.\r\r\n\r\r\nTypes of Revenue:\r\r\n\r\r\n1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered.\r\r\n\r\r\n2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees.\r\r\n\r\r\nFormula for Revenue:\r\r\n\r\r\nThe formula for calculating revenue is based on two goods & services:\r\r\n\r\r\nFor goods:\r\r\nRevenue = Avg unit price x Number of Units sold\r\r\n\r\r\nFor services:\r\r\nRevenue = Avg unit price x Number of Customers served.
Historical Revenue of Suven Pharmaceuticals Ltd
Historical EBITDA of Suven Pharmaceuticals Ltd
PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.
Historical EBITDA of Suven Pharmaceuticals Ltd
Historical Net Profit of Suven Pharmaceuticals Ltd
Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions.\r\r\n\r\r\nNet Profit formula is expressed as:\r\r\n\r\r\nNet Profit = Total Revenue - Total Expense\r\r\n\r\r\nNet Profit Margin Ratio:\r\r\n\r\r\nNet Profit Margin Ratio = Net Profit / Total Revenue
Historical Net Profit of Suven Pharmaceuticals Ltd
Dividend Payout Over Time
Suven Pharmaceuticals Ltd News Hub
Suven Pharmaceuticals consolidated net profit declines 49.61% in the June 2024 quarter
Net profit of Suven Pharmaceuticals declined 49.61% to Rs 60.77 crore in the quarter ended June 2024
Read more
09 Aug 24
Suven Pharmaceuticals to hold board meeting
Suven Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 9 August 2024.
Read more
06 Aug 24
Suven Pharmaceuticals appoints Vivek Sharma as new Executive Chairman
Suven Pharmaceuticals announced the appointment of Vivek Sharma as the new Executive Chairman, effec
Read more
19 Sept 24
Board of Suven Pharmaceuticals approves change in Executive Chairperson
The Board of Suven Pharmaceuticals at its meeting held on 19 September 2024 has taken on record the
Read more
19 Sept 24
Document
Concalls
Jan 2025
PPTFeb 2023
TranscriptDec 2022
TranscriptNov 2022
TranscriptJune 2022
TranscriptFeb 2022
PPTNov 2021
PPTAug 2021
PPTJan 2025
PPTFeb 2023
TranscriptDec 2022
TranscriptNov 2022
TranscriptJune 2022
TranscriptFeb 2022
PPTNov 2021
PPTAug 2021
PPT